/PRNewswire/ WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable.
Chimeric Therapeutics Ltd (ASX:CHM) has entered into a strategic manufacturing partnership with WuXi Advanced Therapies, a global contract testing and.
MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it
/PRNewswire/ WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable.
/PRNewswire/ WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing.